Medexus Pharmaceuticals (MDP) Competitors C$2.82 +0.22 (+8.46%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades MDP vs. FIRE, EPI, OGI, ICC, RIV, LEAF, RX, CRDL, HLS, and TGODShould you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include Supreme Cannabis (FIRE), ESSA Pharma (EPI), Organigram (OGI), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), BioSyent (RX), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), and Green Organic Dutchman (TGOD). These companies are all part of the "drug manufacturers - specialty & generic" industry. Medexus Pharmaceuticals vs. Supreme Cannabis ESSA Pharma Organigram ICC Labs RIV Capital Leaf Mobile BioSyent Cardiol Therapeutics HLS Therapeutics Green Organic Dutchman Supreme Cannabis (TSE:FIRE) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk. Does the MarketBeat Community favor FIRE or MDP? Supreme Cannabis received 59 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Medexus Pharmaceuticals an outperform vote while only 85.33% of users gave Supreme Cannabis an outperform vote. CompanyUnderperformOutperformSupreme CannabisOutperform Votes6485.33% Underperform Votes1114.67%Medexus PharmaceuticalsOutperform Votes5100.00% Underperform VotesNo Votes Is FIRE or MDP more profitable? Medexus Pharmaceuticals has a net margin of 1.00% compared to Supreme Cannabis' net margin of 0.00%. Medexus Pharmaceuticals' return on equity of 3.95% beat Supreme Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Supreme CannabisN/A N/A N/A Medexus Pharmaceuticals 1.00%3.95%4.89% Do analysts rate FIRE or MDP? Medexus Pharmaceuticals has a consensus target price of C$5.25, suggesting a potential upside of 86.17%. Given Medexus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than Supreme Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supreme Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Do insiders and institutionals have more ownership in FIRE or MDP? 8.3% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor FIRE or MDP? In the previous week, Supreme Cannabis had 2 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 2 mentions for Supreme Cannabis and 0 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.00 beat Supreme Cannabis' score of -0.75 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Supreme Cannabis Negative Medexus Pharmaceuticals Neutral Which has stronger valuation and earnings, FIRE or MDP? Medexus Pharmaceuticals has higher revenue and earnings than Supreme Cannabis. Supreme Cannabis is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSupreme CannabisC$53.29M0.00-C$23.65M-C$0.03N/AMedexus PharmaceuticalsC$108.78M0.64C$1.09MC$0.0556.40 SummaryMedexus Pharmaceuticals beats Supreme Cannabis on 15 of the 17 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get Medexus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDP vs. The Competition Export to ExcelMetricMedexus PharmaceuticalsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$69.18MC$1.15BC$5.12BC$6.05BDividend YieldN/A3.04%4.91%5.43%P/E Ratio56.40131.2391.3426.16Price / Sales0.641,962.971,117.701,327.99Price / CashN/A10.1142.6482.04Price / Book2.123.064.793.07Net IncomeC$1.09MC$152.21MC$120.07MC$294.08M7 Day Performance-2.76%-0.51%-1.90%-2.47%1 Month Performance32.39%-1.36%11.45%-0.78%1 Year Performance34.29%98.69%30.63%34.57% Medexus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDPMedexus PharmaceuticalsN/AC$2.82+8.5%C$5.25+86.2%+38.2%C$69.18MC$108.78M56.4098FIRESupreme CannabisN/AC$0.34+3.0%N/AN/AC$259.40MC$53.29M-10.81400News CoverageEPIESSA PharmaN/AC$8.20+7.2%N/A+0.0%C$237.87MN/A-8.2725OGIOrganigram3.1693 of 5 starsC$2.18+3.8%C$3.86+77.2%+36.2%C$236.68MC$149.21M-0.84987Analyst ForecastAnalyst RevisionNews CoverageICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533,684.0095.29N/AGap UpRIVRIV CapitalN/AC$1.50-6.3%N/AN/AC$213.65MC$11.33M-1.6312LEAFLeaf MobileN/AC$2.59-1.9%N/AN/AC$198.42MC$83.74M58.86150RXBioSyentN/AC$11.89-0.8%N/A+32.7%C$137.81MC$33.82M19.97N/ACRDLCardiol TherapeuticsN/AC$1.91+1.1%N/A+59.8%C$133.47MN/A-4.3020News CoverageHLSHLS Therapeutics0.9988 of 5 starsC$3.68+1.1%C$4.13+12.1%+5.5%C$116.99MC$58.89M-3.6091TGODGreen Organic DutchmanN/AN/AN/AN/AC$89.95MC$31.37M-0.6541Gap UpHigh Trading Volume Related Companies and Tools Related Companies Supreme Cannabis Competitors ESSA Pharma Competitors Organigram Competitors ICC Labs Competitors RIV Capital Competitors Leaf Mobile Competitors BioSyent Competitors Cardiol Therapeutics Competitors HLS Therapeutics Competitors Green Organic Dutchman Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:MDP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDP Stock Alerts